If Medicare was allowed to negotiate drug prices, the Medicare Part D program could save $2.8 billion in 1 year on the 20 most commonly prescribed drugs alone, according to a new report from Senator Claire McCaskill, D-Missouri, the top-ranking Democrat on the Senate Homeland Security and Governmental Affairs Committee.
Rising drug costs continues to be a point of focus for Americans and lawmakers. In 2016, Medicare accounted for 29% of all retail prescription spending, but its share is expected to increase to 33% by 2026.
If Medicare was allowed to negotiate drug prices, the Medicare Part D program could save at least $2.8 billion in just 1 year, according to a report released by Senator Claire McCaskill, D-Missouri, the top-ranking Democrat on the Senate Homeland Security and Governmental Affairs Committee.
“When we don’t let Medicare negotiate for better prices, it puts the profits of big pharma ahead of the interests of Missouri seniors,” McCaskill said in a statement. “Getting bulk discounts is something every business does, and the fact that the federal government is prohibited from doing it for Medicare is unconscionable.”
The report compared Medicare Part D spending on the 20 most commonly prescribed brand-name drugs—including anti-diabetic Januvia, nerve pain medicine Lyrica, bronchodilator Symbicort, and blood thinner Xarelto—with prices that had been negotiated by the Department of Veterans Affairs (VA).
The VA’s negotiated drug prices rose at significantly lower rates than the drugs in Medicare Part D, according to the report. The average price for the top 20 most common drugs in Part D increased 59.1% from $151.58 in 2012 to $241.09 in 2017. The negotiated prices increased 44% during that time from $104.10 to $149.88, after adjusting for inflation.
There was only 1 drug, the NovoLog FlexPen, that had a negotiated price that exceeded the list price, but 7 of the top 20 drugs had negotiated prices that were less than half of the list prices, according to the report.
In order to determine the savings Medicare could generate if it also had the ability to negotiate, researchers compared drug prices listed on the Federal Supply Schedule with Medicare Part D expenditures using the 2015 Medicare Expenditure Panel Survey (MEPS). The MEPS entries were matched to negotiated federal prices. According to the report, even accounting for a 17.5% average rebate and increasing negotiated federal prices by $13.46 to account for dispensing costs, Medicare and its beneficiaries could save $2.8 billion if it was able to negotiate for just the top 20 most commonly prescribed brand-name drugs.
“The significant variation between Medicare Part D drug prices and negotiated federal drug prices—and the potential costs savings from extending negotiated prices to other federal drug benefit programs—merits further investigation,” the report concluded.
CMS released a final rule to help patients obtain Children’s Health Insurance Program (CHIP) coverage and issued a proposed rule to update Medicare payment policies and rates for inpatient rehabilitation facilities; debate over if gift card incentives are acceptable in health care marketing.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
A global AIDS program that was in limbo for months got temporary relief after congressional negotiators agreed to a 1-year renewal in the next government funding package; the outcome of the November presidential election could determine the state of fetal tissue research in the US; federal officials and industry executives failed to make improvements that stop hacking attacks.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Fragmented Payer System, Vulnerable Supply Chain Among Threats to Accessing Essential Medicines
March 13th 2024During a session of the 2024 V-BID Summit, panelists Stacie Dusetzina, PhD, and Inma Hernandez, PharmD, PhD, discussed how access to essential medications is curtailed not just by the longstanding complexities of insurance design but also by emerging threats such as supply chain weaknesses and cyberattacks.
Read More
Most private health insurers have yet to publish criteria for when they will cover postpartum depression drug, zuranolone; state lawmakers are increasingly opposing health care mergers that they believe do not serve the public interest; Medicaid extensions made in 2021 led to a 40% decline in postpartum lack of insurance.
Read More